Pivotal data at ats 2021 show dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children

Tarrytown, n.y. and paris, may 17, 2021 /prnewswire/ --  dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized phase 3 trial, with potential to be best-in-class treatment for these patients fda decision for children with moderate-to-severe asthma expected by october 21, 2021 regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that detailed results from a phase 3 trial showed dupixent® (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, with evidence of type 2 inflammation.
REGN Ratings Summary
REGN Quant Ranking